BioCardia

Historical price data

BioCardia's mission is to advance cardiovascular regenerative medicine through its targeted, minimally invasive delivery platforms. Its core achievement is the development of the Helix™ transendocardial delivery system, which has been used in multiple clinical trials for heart failure. The company's strategy is twofold: advancing its own autologous cell therapy programs while actively seeking partnerships to deploy its delivery technology with third-party therapeutics. Despite its innovative approach, BioCardia operates as a micro-cap company facing significant financial and execution challenges.

Proprietary, catheter-based Helix™ Transendocardial Delivery System and Morph® steerable guide for minimally invasive, targeted delivery of cell and gene therapies directly into the heart muscle.

Faces competition from other heart failure cell therapy developers (e.g., Mesoblast) and from large medical device firms capable of developing similar delivery catheters. Its first-mover FDA clearance for cardiac cell delivery is a key, but potentially erodible, advantage.